The Outcome of Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization

肝細胞癌實施併用抗癌藥物的動脈栓塞術之治療成績

謝明裕(Ming-Yuh Hsieh) ； 吳定國(Ding-Kwo Wu) ； 盧勝男(Sheng-Nan Lu) ； 王良彥(Liang-Yen Wang) ； 張文宇(Wen-Yu Chang)

《The Kaohsiung Journal of Medical Sciences》 6卷11期 (1990/11) Pp. 628-635

https://doi.org/10.6452/KJMS.199011.0628

摘要

Transcatheter arterial embolization (TAE) has now been widely accepted in the treatment of hepatoceliular carcinoma (HCC). Forty-five patients with tissue proven HCC received TAE and were followed up for more than 6 months; 28 of them were followed for more than one year and 13 for 2 years. The embolic materials used were Lipiodol 0.1-0.2 mi/cm2 (tumor area of its maximal diameter), which was prepared by pumping with contrast agent at a ratio of 1:2 and mixed with anticancer drugs (Mitomycin C: 8-10 mg or Adriamycin 40-50 mg), gelform particles 1-2 mm in size were subsequently embolized. The postembolization syndrome: adbominal pain, fever, nausea and vomiting usually subsided within 1-3 weeks. The overall cumulative half¡Xyear, 1-year and 2-year survival rates were 77.8%, 57.1% and 46.2%, respectively. Cases with regular follow-up and those with massive type without satellites, esp. when tumor size ＜5cm, had better survival rates. In contrast, portal vein thrombosis and big tumors (especially with satellitesi indicated poor prognosis. In addition, actively treated coexisting peptic ulcer and/or esophageal varices in HCC patients also improved TAE results.

並列摘要

Transcatheter arterial embolization (TAE) has now been widely accepted in the treatment of hepatoceliular carcinoma (HCC). Forty-five patients with tissue proven HCC received TAE and were followed up for more than 6 months; 28 of them were followed for more than one year and 13 for 2 years. The embolic materials used were Lipiodol 0.1-0.2 mi/cm2 (tumor area of its maximal diameter), which was prepared by pumping with contrast agent at a ratio of 1:2 and mixed with anticancer drugs (Mitomycin C: 8-10 mg or Adriamycin 40-50 mg), gelform particles 1-2 mm in size were subsequently embolized. The postembolization syndrome: adbominal pain, fever, nausea and vomiting usually subsided within 1-3 weeks. The overall cumulative half¡Xyear, 1-year and 2-year survival rates were 77.8%, 57.1% and 46.2%, respectively. Cases with regular follow-up and those with massive type without satellites, esp. when tumor size ＜5cm, had better survival rates. In contrast, portal vein thrombosis and big tumors (especially with satellitesi indicated poor prognosis. In addition, actively treated coexisting peptic ulcer and/or esophageal varices in HCC patients also improved TAE results.

並列關鍵字

alpha-fetoprotein (AFP) ； hepatocellular carcinoma (HCC) ； transcatheter arterial embolization (TAE)